Abstract
Purpose :
Considered the gold standard in assessing location of choroidal neovascular (CNV) lesions, fluorescin angiography (FA) is the primary imaging modality used to determine CNV lesion eligibility in clinical trials. With structural spectral domain optical coherence tomography (SD-OCT), it is now possible to determine location of CNV on B scans. In this report, we compare the agreement of SD-OCT vs. FA in identifying CNV lesion location. The purpose of our study was to determine the agreement of SD-OCT vs. FA in assessing subfoveal and juxtafoveal location of CNV lesions in eyes with neovascular age-related macular degeneration (AMD).
Methods :
In this cross-sectional study of FA and SD-OCT scans, we included 394 eyes with active treatment naïve CNV visible on FA. We independently graded for the presence or absence of CNV lesion at center point (subfoveal), within the central subfield and outside central subfield. All images were graded by a central reading center.
Results :
With FA, 244 eyes had CNV at center point, 111 within central subfield and 39 outside central subfield. Exact agreement on CNV location between FA and SD-OCT for the three categories was 68%. Almost 59% of eyes with CNV within central subfield on FA showed CNV at center point on SD-OCT. The addition of SD-OCT along with FA to determine eligibility criteria for subfoveal CNV location would increase enrollment by 27%.
Conclusions :
SD-OCT provides important supplementary information for determining location of CNV lesions in patients with AMD. Future clinical trial designs may incorporate both FA and SD-OCT in eligibility criteria.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.